Here's why the Imugene (ASX:IMU) share price is jumping 5% today

The Imugene Limited (ASX: IMU) share price is rising on the back of news the immuno-oncology company has entered a new licensing agreement.

| More on:
three excited doctors with hands in the air

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Imugene Limited (ASX: IMU) share price is leaping higher today on the back of news the immuno-oncology company has entered into a licensing agreement.

The agreement will see Imugene licensing the patents for a novel combination immunotherapy targeting cancer cells.

At the time of writing, the Imugene share price is trading 5.3% higher than yesterday's close, with shares in the company swapping hands for 34.75 cents.

Let's take a closer look at the announcement Imugene made this morning.

Cancer therapy licensing agreement

Imugene has entered into a licensing agreement with City of Hope, an independent cancer research and treatment centre. The technology under the license is an extension of chimeric antigen receptor (CAR) T cell cancer therapy.

According to Lymphoma Australia, CAR T cell therapy uses a person's T cells, which are a type of white blood cell, to attack cancer cells. CAR T cell therapy makes a person's white blood cells attracted to CD19 protein, which is found on the surface of some types of cancer cells. The white blood cells can then attack the cancer.

As solid tumours don't naturally produce CD19, they can't currently be treated with CAR T cell therapy.

Under the licensing agreement, Imugene will license City of Hope's CD19 therapy. The therapy is a CAR T cell therapy using City of Hope's oncolytic virus, onCARlytics.

OnCARlytics has so far been successful in making solid tumours produce the CD19 protein.

Imugene states that targeting solid cancers with T cell therapy is the technology's "holy grail", as current Federal Drug Administration (FDA) approved CD19 CAR T drugs only work to treat blood cancers.

The first clinical trial is expected to start next year. Within it, onCARlytics will be combined with CAR T therapy to target solid tumours.

The trial will test the safety and efficacy of the treatment combination in humans.

So far, researchers at City of Hope have been able to successfully use onCARlytics to produce CD19 in triple-negative breast, pancreatic, prostate, ovarian, head and neck, and brain cancer cells. They have also successfully combined onCARlytics with CAR T cell therapy in mice studies. The findings included a significant number of mice being cured of cancer with prolonged protective anti-tumour immunity.

Commentary from management

Imugene's managing director and CEO Leslie Chong commented on the therapy. She said:

The CAR T cell field currently only treats ~10% of all cancers such as blood or liquid tumours, whereas this technology has the potential to open up the solid tumour market.

Imugene share price snapshot

The Imugene share price is having a fantastic year so far on the ASX, with today's news bringing its latest boost.

Currently, the Imugene share price has gained around 240% since the start of 2021. It's also up a whopping 1,033% since this time last year.

The company has a market capitalisation of around $1.6 billion, with approximately 4.7 billion shares outstanding.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Broker says this ASX 200 biotech stock is a top buy

Let's see what Bell Potter is saying about this biotech.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why CSL shares are a buy today despite the looming Trump tariffs

A leading expert believes CSL shares are still trading for a bargain today. Here's why.

Read more »

A businesswoman pulls her glasses down in shock to look at the bad news on her computer.
Healthcare Shares

Why did the Telix share price just crash 16%?

Investors are sending the Telix share price plunging today. But why?

Read more »

Broker analysing the share price.
Healthcare Shares

Expert: 2 ASX healthcare stocks to avoid before reporting season

Not all healthcare stocks are created equal.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Should I buy Pro Medicus or CSL shares ahead of earnings season?

The ASX healthcare sector may be currently undervalued.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why Mesoblast shares can keep storming higher

More big returns could be on the way for buyers of this high risk stock according to Bell Potter.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »